Biopharmaceuticals - Université de Tours Accéder directement au contenu
Article Dans Une Revue Therapeutic Drug Monitoring Année : 2017

Biopharmaceuticals

Résumé

Biopharmaceuticals are primarily therapeutic proteins developed to perform specific functions by acting on the disease pathophysiology. Compared with low-molecular chemically synthesized drugs, production of biopharmaceuticals is much more complex and routes of administration and pharmacokinetics differ. Biopharmaceuticals are blockbusters in the treatment of inflammatory diseases, such as psoriasis, multiple sclerosis, rheumatic diseases, and inflammatory bowel diseases, and the introduction of these drugs has revolutionized treatment. Disadvantages include their high costs and the fact that they can evoke antidrug antibodies leading to decreased efficacy. Treatment can be optimized through the development of dosing algorithms and cost can be reduced by biosimilars, after a comparable biological activity, safety, and efficacy have been demonstrated.
Fichier non déposé

Dates et versions

hal-01980742 , version 1 (14-01-2019)

Identifiants

Citer

Ann Gils, Antonio Bertolotto, Denis Mulleman, Theodora Bejan-Angoulvant, Paul Declerck. Biopharmaceuticals. Therapeutic Drug Monitoring, 2017, 39 (4), pp.308-315. ⟨10.1097/FTD.0000000000000385⟩. ⟨hal-01980742⟩

Collections

UNIV-TOURS CNRS
51 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More